March 13th Options Now Available For Gilead Sciences (GILD)

The article outlines two Gilead Sciences (GILD) options strategies: selling a $135 put (bid $2.31) would set an effective purchase price of $132.69 versus the current share price of $139.67, with a 64% chance of expiring worthless and a 1.71% return (14.54% annualized) if it does. A covered call at the $141 strike (bid $3.55) on shares bought at $139.67 yields 3.49% total return to assignment by the March 13 expiration, with a 51% chance of expiring worthless and a 2.54% YieldBoost (21.60% annualized); implied volatility is ~32% versus a trailing 12‑month volatility of 29%.

Analysis

Market structure: Short-dated option sellers and yield-hungry retail/institutional accounts are the direct beneficiaries — collecting 1.7–3.5% premiums over ~6 weeks (March 13 expiry). Market makers and brokers also benefit from flow; downside losers are holders exposed to abrupt biotech-specific shocks (FDA, trial data) that can gap-stock beyond covered-call strikes. The ~32% IV vs 29% realized vol signals modestly rich near-term option premium, supporting premium-selling but not at scale without risk controls.

Risk assessment: Tail risks are binary biotech events (FDA rejections, negative readouts, patent/litigation rulings) that can move GILD +/-10–30% within days and blow past strikes or cause heavy assignment/margin calls. Immediate window (days–6 weeks): option decay dominates; short-term (1–3 months): earnings/clinical calendar and IV shifts matter; long-term (quarters–years): pipeline success, competitive share loss, and interest-rate-driven valuation multiple compression drive returns. Hidden dependencies include assignment liquidity, financing costs for assigned shares, and dealer delta-hedging that can exacerbate moves.

Trade implications: If willing to own GILD, cash-secured sell-to-open the Mar13 $135 put (collect $2.31, net basis $132.69) sized to 1–2% portfolio; cap risk with a $135/$125 put spread to limit worst-case to ~$8. If already long, sell the Mar13 $141 covered call (collect $3.55) or convert to a $141/$145 call credit spread to preserve some upside. Avoid naked short premium >2–3% portfolio if imminent clinical/earnings catalyst or if IV spikes >40%.

Contrarian angles: The crowd treats these as “income” trades but underprices binary upside — a positive trial or buyout can easily push GILD >10% and render covered-call income insignificant vs opportunity cost. Conversely, implied vol only ~3pts rich vs realized; if no near-term catalysts, short-premium strategies may be underpriced edge. Historical analog: biotech covered-call sellers lost when binary events occurred (e.g., post-readout gaps); manage via defined-risk spreads and strict roll/exit thresholds.

Key Decisions for Investors

• Sell cash‑secured GILD Mar13 2026 $135 put (sell‑to‑open) to collect $2.31 — target position size = 1% of portfolio (one contract ≈100 shares) if willing to own at $132.69; immediately place stop/close if GILD < $130 or IV > 40%.
• If long GILD shares, sell Mar13 $141 covered call (collect $3.55) for a 3.49% return to strike; convert to a $141/$145 call credit spread to limit assignment risk and cap upside loss if share rallies >3% — size 1–2% portfolio.
• Prefer defined‑risk alternative: sell $135/$125 put spread (Mar13) instead of naked put — max loss ~$10 − premium; use this if unwilling to own outright but want ~1–2% short-dated yield exposure.
• Relative trade: overweight GILD vs IBB (long GILD, short IBB at 0.5–0.8 beta) for 1–3 months if conviction in GILD’s idiosyncratic stability; trim or unwind if GILD underperforms by >5% vs IBB or upcoming clinical/earnings date within 14 days.